Chardan Capital maintains Buy rating and $240 target on Palvella Therapeutics
Chardan Capital maintained a Buy rating on Palvella Therapeutics and reiterated a $240.00 price target, implying 59.4% upside versus the Sep 18 close of $150.56.
Chardan Capital maintained a Buy rating on Palvella Therapeutics and reiterated a $240.00 price target, implying 59.4% upside versus the Sep 18 close of $150.56.